168 related articles for article (PubMed ID: 21811593)
1. Prediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid search-projection pursuit regression method.
Du H; Hu Z; Bazzoli A; Zhang Y
PLoS One; 2011; 6(7):e22367. PubMed ID: 21811593
[TBL] [Abstract][Full Text] [Related]
2. QSAR of aromatic substances: EGFR inhibitory activity of quinazoline analogues.
Deeb O; Clare BW
J Enzyme Inhib Med Chem; 2008 Dec; 23(6):763-75. PubMed ID: 18608750
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain.
Park JH; Liu Y; Lemmon MA; Radhakrishnan R
Biochem J; 2012 Dec; 448(3):417-23. PubMed ID: 23101586
[TBL] [Abstract][Full Text] [Related]
4. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Wood ER; Truesdale AT; McDonald OB; Yuan D; Hassell A; Dickerson SH; Ellis B; Pennisi C; Horne E; Lackey K; Alligood KJ; Rusnak DW; Gilmer TM; Shewchuk L
Cancer Res; 2004 Sep; 64(18):6652-9. PubMed ID: 15374980
[TBL] [Abstract][Full Text] [Related]
5. A comparative QSAR analysis of quinazoline analogues as tyrosine kinase (erbB-2) inhibitors.
Noolvi MN; Patel HM; Bhardwaj V
Med Chem; 2011 May; 7(3):200-12. PubMed ID: 21486203
[TBL] [Abstract][Full Text] [Related]
6. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor.
Ward WH; Cook PN; Slater AM; Davies DH; Holdgate GA; Green LR
Biochem Pharmacol; 1994 Aug; 48(4):659-66. PubMed ID: 8080438
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Assefa H; Kamath S; Buolamwini JK
J Comput Aided Mol Des; 2003 Aug; 17(8):475-93. PubMed ID: 14703120
[TBL] [Abstract][Full Text] [Related]
9. In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors.
Asadollahi-Baboli M
Mol Divers; 2016 Aug; 20(3):729-39. PubMed ID: 27209475
[TBL] [Abstract][Full Text] [Related]
10. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.
Stamos J; Sliwkowski MX; Eigenbrot C
J Biol Chem; 2002 Nov; 277(48):46265-72. PubMed ID: 12196540
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.
Rewcastle GW; Denny WA; Bridges AJ; Zhou H; Cody DR; McMichael A; Fry DW
J Med Chem; 1995 Sep; 38(18):3482-7. PubMed ID: 7658435
[TBL] [Abstract][Full Text] [Related]
12. Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
Song J; Jang S; Lee JW; Jung D; Lee S; Min KH
Bioorg Med Chem Lett; 2019 Feb; 29(3):477-480. PubMed ID: 30554954
[TBL] [Abstract][Full Text] [Related]
13. Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors.
Sun XQ; Chen L; Li YZ; Li WH; Liu GX; Tu YQ; Tang Y
Acta Pharmacol Sin; 2014 Feb; 35(2):301-10. PubMed ID: 24335842
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the epidermal growth factor receptor protein tyrosine kinase: a quantitative structure-activity relationship analysis.
Singh P; Kumar R
J Enzyme Inhib; 1998 Apr; 13(2):125-34. PubMed ID: 9629532
[TBL] [Abstract][Full Text] [Related]
15. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
Rho JK; Choi YJ; Jeon BS; Choi SJ; Cheon GJ; Woo SK; Kim HR; Kim CH; Choi CM; Lee JC
Mol Cancer Ther; 2010 Dec; 9(12):3233-43. PubMed ID: 21159609
[TBL] [Abstract][Full Text] [Related]
17. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model.
Jin Y; Iwata KK; Belldegrun A; Figlin R; Pantuck A; Zhang ZF; Lieberman R; Rao J
Mol Cancer Ther; 2006 Jul; 5(7):1754-63. PubMed ID: 16891461
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.
Xu Y; Liu H; Chen J; Zhou Q
Cancer Biol Ther; 2010 Apr; 9(8):572-82. PubMed ID: 20404520
[TBL] [Abstract][Full Text] [Related]
20. 2D QSAR and Virtual Screening based on Pyridopyrimidine Analogs of Epidermal Growth Factor Receptor Tyrosine Kinase.
Sugunakala S; Selvaraj S
Curr Comput Aided Drug Des; 2016; 12(3):229-240. PubMed ID: 27264509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
